
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is well-positioned to capture a significant chunk of the diabetic treatment market with its innovative and potentially game-changing drug candidate icovamenib. The company also has a strong pipeline, with BMF-650 showing promise as a potential treatment for obesity, providing additional growth opportunities. Strong clinical data and upcoming catalysts make Biomea Fusion a company to watch in the pharmaceutical industry.
Bears say
Biomea Fusion is a clinical-stage company that is heavily reliant on the success of its two core drug candidates, icovamenib and BMF-650, which both target diabetes and obesity. However, the company has a history of operating losses and faces significant financial risks, including the possibility of dilutive capital raises. Additionally, while icovamenib has shown promising results in early trials, it still has a long development path ahead and faces competition from other menin inhibitors. Overall, the company's current outlook is negative due to uncertainty surrounding its drug candidates and financial stability.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares